Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis-Reference-Cited by-同舟云学术

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis

Published:2022-09 Issue:3 Volume:166 Page:425-431
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Cadoo Karen,Simpkins Fiona,Mathews Cara,Liu Ying L.,Provencher Diane,McCormick Colleen,ElNaggar Adam C.,Altman Alon D.,Gilbert Lucy,Black Destin,Kabil Nashwa,Bennett James,Munley Jiefen,Aghajanian Carol

Funder

Merck Sharp and Dohme

AstraZeneca

Merck

Memorial Sloan-Kettering Cancer Center

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference25 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol.,2013

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021